Summary

The global AI in biotechnology market is projected to reach USD 22,716.5 million by 2035 from USD 4,156.9 million in 2025, at a high CAGR of 18.5% during the forecast period. The market is progressing steadily, driven by the growing adoption of AI for predictive analytics in drug safety and efficacy, the increasing use of AI-powered automation in laboratory processes, and the rising demand for cost-efficient and accelerated research pipelines. Moreover, the expanding availability of large-scale biological datasets, advancements in cloud computing infrastructure, and supportive government initiatives promoting AI in life sciences further propel market growth. The convergence of AI with emerging biotechnologies is enabling faster innovation, improved decision-making, and more personalized healthcare solutions. https://mnmimg.marketsandmarkets.com/Images/ai-in-biotechnology-market-img-overview1.webp “The research & development segment of the AI in biotechnology market is the largest segment during the forecast period.” Based on function, the research & development (R&D) segment accounted for the largest share of the AI in biotechnology market and is projected to maintain its lead in the coming years. This dominance is driven by the increasing use of AI to accelerate drug discovery, optimize molecular design, and predict compound efficacy and safety. AI-powered tools enable researchers to analyze large-scale genomic, proteomic, and clinical datasets more efficiently, reducing experimental timelines and costs. Additionally, the integration of machine learning algorithms with high-throughput screening and automated laboratory platforms is enhancing the precision and scalability of R&D processes. As biotech companies strive to bring novel therapeutics to market faster, the adoption of AI in R&D continues to be a key growth driver. “Based on the end user, the pharmaceutical companies segment accounted for the largest share of AI in biotechnology market during the forecast period.” The pharmaceutical companies segment accounted for the largest share of the AI in biotechnology market during the forecast period. This growth is driven by the increasing adoption of AI for accelerating drug discovery, optimizing clinical trial design, and predicting drug efficacy and safety profiles. Pharmaceutical firms are leveraging AI to analyze large-scale biological and clinical datasets, identify novel drug targets, and streamline R&D workflows, reducing time and cost. Additionally, AI-enabled predictive modeling and virtual screening tools help companies make data-driven decisions, enhance success rates, and bring new therapies to market more efficiently. The rising demand for personalized medicine and the pressure to innovate rapidly further reinforce the adoption of AI within the pharmaceutical sector. “Asia Pacific is projected to witness the highest growth rate during the forecast period.” The Asia Pacific region is projected to witness the highest growth rate in the AI in biotechnology market during the forecast period. This rapid expansion is driven by a strong focus on technological advancement and research excellence. Countries across the region are strengthening their innovation ecosystems through enhanced infrastructure, academic-industry partnerships, and cross-border collaborations. The growing emphasis on precision medicine, data-driven healthcare, and sustainable biomanufacturing is also creating new opportunities for market development. Moreover, supportive regulatory frameworks and increasing public-private initiatives position Asia Pacific as a global hub for next-generation biotechnological progress. In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the AI in biotechnology marketplace. The breakdown of primary participants is as mentioned below: ? By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20% ? By Designation - C-Level: 35%, Director Level: 25%, and Others: 40% ? By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Latin America: 3%, Middle East & Africa: 2% Key Players in the AI in Biotechnology Market The key players operating in the AI in biotechnology market include NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schr?dinger, Inc. (US), BenevolentAI (UK), Data4Cure, Inc. (US), Qiagen (Germany), Insilico Medicine (US), DNAnexus, Inc. (US), Tempus (US), SOPHiA GENETIC (Switzerland), Predictive Oncology (US), Deep Genomics (Canada), NuMedii, Inc. (US), XtalPi Inc. (China), Iktos (France), BPGbio, Inc. (US), Eurofins Discovery (US), VeriSIM Life (US), Lifebit (UK), Verge Genomics (US), Logica (US), American Chemical Society (US), and Aganitha AI Inc. (India). Research Coverage The report analyzes the AI in biotechnology market and aims to estimate the market size and future growth potential of various market segments, based on offering, function, deployment mode, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies. Reasons to Buy the Report This report will benefit established firms as well as new entrants and smaller firms in gauging the market pulse, which in turn will help them capture a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market. This report provides insights into the following: ? Analysis of key drivers (growing cross-industry collaborations and partnerships, growing need to reduce time and cost of drug discovery and development, rising adoption of AI in precision medicine, improving computing power and declining hardware cost), restraints (high implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies, data privacy risks and compliance challenges for AI in biotechnology), opportunities (integrating AI and big data in precision medicine for biotechnology advancement, surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations, innovation across healthcare, agriculture, and environmental science for global growth) challenges (data quality and interpretability issues that hinder AI integration and trustworthiness, AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges) influencing the growth of the AI in biotechnology market ? Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in biotechnology market ? Market Development: Comprehensive information on the lucrative emerging markets, offering, function, deployment mode, end user, and region ? Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in biotechnology market ? Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in biotechnology market, like NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schr?dinger Inc. (US), and BenevolentAI (UK)

ページTOPに戻る

Table of Contents

＜P＞1 INTRODUCTION 53
1.1 STUDY OBJECTIVES 53
1.2 MARKET DEFINITION 53
1.3 STUDY SCOPE 54
1.3.1 MARKETS COVERED & REGIONAL SCOPE 54
1.3.2 INCLUSIONS & EXCLUSIONS 55
1.3.3 YEARS CONSIDERED 56
1.3.4 CURRENCY CONSIDERED 57
1.4 RESEARCH LIMITATIONS 57
1.5 STAKEHOLDERS 58
2 RESEARCH METHODOLOGY 59
2.1 RESEARCH DATA 59
2.1.1 SECONDARY DATA 60
2.1.1.1 Key data from secondary sources 61
2.1.2 PRIMARY DATA 61
2.1.2.1 Key data from primary sources 63
2.1.2.2 Insights from primary experts 64
2.2 MARKET SIZE ESTIMATION 65
2.3 DATA TRIANGULATION 69
2.4 MARKET SHARE ESTIMATION 69
2.5 RESEARCH ASSUMPTIONS 70
2.6 RESEARCH LIMITATIONS 70
2.6.1 METHODOLOGY-RELATED LIMITATIONS 70
2.6.2 SCOPE-RELATED LIMITATIONS 70
2.7 RISK ASSESSMENT 71
3 EXECUTIVE SUMMARY 72
4 PREMIUM INSIGHTS 76
4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW 76
4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION 77
4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING AND COUNTRY 78
4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT 79
4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES 79
?
5 MARKET OVERVIEW 80
5.1 INTRODUCTION 80
5.2 MARKET DYNAMICS 80
5.2.1 DRIVERS 82
5.2.1.1 Growing cross-industry collaborations and partnerships 82
5.2.1.2 Increasing need to reduce time and cost of drug discovery & development 83
5.2.1.3 Rising adoption of AI in precision medicine 84
5.2.1.4 Increasing investments in semiconductor chipsets 85
5.2.2 RESTRAINTS 85
5.2.2.1 High implementation costs 85
5.2.2.2 Data privacy risks and compliance challenges 85
5.2.3 OPPORTUNITIES 86
5.2.3.1 Rise of advanced analytics and predictive modeling 86
5.2.3.2 Surge in biotechnology investments 87
5.2.3.3 Innovations across healthcare, agriculture, and environmental science 87
5.2.4 CHALLENGES 88
5.2.4.1 Data quality and interpretability issues 88
5.2.4.2 Shortage of qualified experts and evolving regulatory challenges 88
5.3 UNMET NEEDS AND WHITE SPACES 89
5.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 90
5.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 91
6 INDUSTRY TRENDS 92
6.1 EVOLUTION OF AI IN BIOTECHNOLOGY 92
6.2 PORTER’S FIVE FORCES ANALYSIS 94
6.2.1 BARGAINING POWER OF SUPPLIERS 95
6.2.2 BARGAINING POWER OF BUYERS 95
6.2.3 THREAT OF SUBSTITUTES 95
6.2.4 THREAT OF NEW ENTRANTS 95
6.2.5 INTENSITY OF COMPETITIVE RIVALRY 95
6.3 MACROECONOMICS INDICATORS 95
6.3.1 INTRODUCTION 95
6.3.2 GDP TRENDS AND FORECAST 96
6.3.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 96
6.4 VALUE CHAIN ANALYSIS 96
6.5 ECOSYSTEM ANALYSIS 97
6.6 PRICING ANALYSIS 100
6.6.1 INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY OFFERING,
BY KEY PLAYERS (2024) 100
6.6.2 INDICATIVE PRICING OF AI IN BIOTECHNOLOGY, BY REGION 101
6.7 KEY CONFERENCES AND EVENTS, 2025?2026 101
6.8 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 102
6.9 INVESTMENT AND FUNDING SCENARIO 103
6.10 CASE STUDY ANALYSIS 103
6.10.1 CASE STUDY 1: RAPID TRAINING OF PROTEIN MODELS USING NVIDIA DGX CLOUD 103
6.10.2 CASE STUDY 2: IMPROVED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION 104
6.10.3 CASE STUDY 3: ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS 104
6.11 IMPACT OF 2025 US TARIFF ON AI IN BIOTECHNOLOGY MARKET 105
6.11.1 INTRODUCTION 105
6.11.2 KEY TARIFF RATES 105
6.11.3 PRICE IMPACT ANALYSIS 106
6.11.4 IMPACT ON COUNTRIES/REGIONS 106
6.11.4.1 North America 106
6.11.4.2 Europe 107
6.11.4.3 Asia Pacific 107
6.11.5 IMPACT ON END-USE INDUSTRIES 107
6.11.5.1 Pharmaceutical companies 107
6.11.5.2 Biotechnology companies 107
6.11.5.3 Research institutes and labs 108
6.11.5.4 Healthcare providers 108
6.11.5.5 Contract Research Organizations (CROs) 108
7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,
AND AI ADOPTIONS 109
7.1 KEY EMERGING TECHNOLOGIES 109
7.1.1 NATURAL LANGUAGE PROCESSING (NLP) 109
7.1.2 PREDICTIVE ANALYTICS 109
7.2 COMPLEMENTARY TECHNOLOGIES 109
7.2.1 CLOUD COMPUTING 109
7.2.2 BIG DATA ANALYTICS 109
7.3 TECHNOLOGY/PRODUCT ROADMAP 110
7.4 PATENT ANALYSIS 111
7.4.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY 111
7.4.2 JURISDICTION AND TOP APPLICANT ANALYSIS 111
7.5 FUTURE APPLICATIONS 116
7.5.1 AI-ENABLED PRECISION DISCOVERY AND MULTI-OMICS INTEGRATION 116
7.5.2 GENERATIVE BIOLOGY AND AUTOMATED DESIGN OF MOLECULES, PROTEINS, AND GENETIC SYSTEMS 117
?
7.6 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET 117
7.6.1 INTRODUCTION 117
7.6.2 TOP USE CASES AND MARKET POTENTIAL 118
7.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 119
7.6.3.1 Drug discovery and development market 119
7.6.3.2 Genomics and bioinformatics market 120
7.6.3.3 Medical imaging & diagnostics market 120
7.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN AI IN BIOTECHNOLOGY MARKET 120
7.6.4.1 User readiness 120
7.6.4.1.1 Pharmaceutical companies 120
7.6.4.1.2 Biotechnology companies 120
7.6.4.2 Impact assessment 121
7.6.4.2.1 User A: Pharmaceutical companies 121
7.6.4.2.1.1 Implementation 121
7.6.4.2.1.2 Impact 121
7.6.4.2.2 User B: Biotechnology companies 121
7.6.4.2.2.1 Implementation 121
7.6.4.2.2.2 Impact 122
7.6.5 CASE STUDY ON AI/GENERATIVE AI IMPLEMENTATION 122
7.6.5.1 Case Study 1: Enhanced operations and revenue using AI-driven real-world data analytics 122
7.6.5.2 Case study 2: Advance AI-powered target discovery with proprietary AI platform 123
8 REGULATORY LANDSCAPE 124
8.1 REGIONAL REGULATIONS AND COMPLIANCE 124
8.1.1 NORTH AMERICA 124
8.1.2 EUROPE 125
8.1.3 ASIA PACIFIC 126
8.1.4 LATIN AMERICA 127
8.1.5 MIDDLE EAST & AFRICA 127
8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128
8.3 INDUSTRY STANDARDS 130
9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 131
9.1 DECISION-MAKING PROCESS 131
9.2 INFLUENCE OF STAKEHOLDERS AND BUYING CRITERIA 131
9.2.1 BUYING CRITERIA 132
9.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 133
9.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 133
9.5 END-USER EXPECTATIONS 134
10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING 135
10.1 INTRODUCTION 136
10.2 END-TO-END SOLUTIONS 137
10.2.1 GROWING USE OF ADVANCED ALGORITHMS FOR BETTER PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH 137
10.3 NICHE SOLUTIONS 138
10.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION 138
10.4 TECHNOLOGIES 139
10.4.1 ADOPTION OF ADVANCED TECHNOLOGIES FOR DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH 139
10.5 SERVICES 141
10.5.1 CONSULTING SERVICES 142
10.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption 142
10.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT 143
10.5.2.1 Increasing precision and efficiency in IT support services to boost demand 143
10.5.3 TRAINING & EDUCATION SERVICES 144
10.5.3.1 Need for skilled talent for better training & education services to drive market 144
10.5.4 POST-SALES & MAINTENANCE SERVICES 145
10.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market 145
11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 147
11.1 INTRODUCTION 148
11.2 RESEARCH & DEVELOPMENT 149
11.2.1 DRUG DISCOVERY 151
11.2.1.1 Molecular design & optimization 153
11.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market 153
11.2.1.2 Biomarker discovery 154
11.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand 154
11.2.1.3 Structure-activity relationship (SAR) modeling 155
11.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth 155
11.2.2 CLINICAL DEVELOPMENT 156
11.2.2.1 Trial design 158
11.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market 158
11.2.2.2 Site selection 159
11.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth 159
11.2.2.3 Recruitment 160
11.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand 160
11.2.2.4 Clinical data assessment 161
11.2.2.4.1 Ability of clinical data assessment for efficient and accurate of data interpretation to propel market 161
11.2.2.5 Predictive toxicity & risk monitoring 162
11.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates 162
11.2.2.6 Monitoring & drug adherence 163
11.2.2.6.1 Enhanced patient compliance with monitoring and drug adherence to drive market 163
11.2.2.7 Real-world evidence (RWE) analysis 164
11.2.2.7.1 Enhanced safety monitoring and economic evaluation with RWE analysis to propel growth 164
11.3 REGULATORY COMPLIANCE 165
11.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH 165
11.4 MANUFACTURING & SUPPLY CHAIN 166
11.4.1 SUPPLY CHAIN PLANNING 168
11.4.1.1 Increasing demand for real-time data analytics to accelerate market growth 168
11.4.2 INVENTORY MANAGEMENT 169
11.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel market growth 169
11.4.3 LOGISTICS OPTIMIZATION 170
11.4.3.1 Ability of AI for increased collaboration and transparency in biotechnology logistics to aid growth 170
11.4.4 DEMAND FORECASTING 171
11.4.4.1 Ability to integrate data for a reliable demand forecast to fuel market growth 171
11.4.5 PREDICTIVE MAINTENANCE 172
11.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand 172
11.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS 173
11.5 LAUNCH & COMMERCIAL 174
11.5.1 LAUNCH COORDINATION 176
11.5.1.1 Increasing product launch success rates through predictive analytics to boost adoption 176
11.5.2 PATIENT ENGAGEMENT 177
11.5.2.1 Real-time patient feedback for better health outcomes to support growth 177
11.5.3 MARKETING OPERATIONS 178
11.5.3.1 Enhanced marketing performance with AI to boost market growth 178
11.5.4 PREDICTIVE PRICING 179
11.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption 179
11.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT 180
11.6.1 MEDICATION ADHERENCE 182
11.6.1.1 Growing demand for personalized treatment plans to drive market 182
11.6.2 ADVERSE EVENT REPORTING 184
11.6.2.1 Faster post-market surveillance and enhanced drug safety to drive demand 184
11.6.3 PATIENT MONITORING 185
11.6.3.1 Rise of remote healthcare solutions to boost market demand 185
11.6.4 COMPLIANCE MONITORING 186
11.6.4.1 Increasing complexity of regulatory requirements to drive adoption 186
11.6.5 PATIENT SUPPORT PROGRAMS 187
11.6.5.1 Growing interest in patient-centered care to support market growth 187
11.7 CORPORATE 188
11.7.1 RISK MANAGEMENT 189
11.7.1.1 Rising expenditure for drug development to support growth 189
11.7.2 COMPLIANCE MONITORING 190
11.7.2.1 Strict guidelines for complex regulatory landscapes to aid market growth 190
11.7.3 SALES FORCE OPTIMIZATION 191
11.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization 191
11.7.4 OTHER CORPORATE FUNCTIONS 192
12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 194
12.1 INTRODUCTION 195
12.2 CLOUD-BASED SOLUTIONS 195
12.2.1 PUBLIC CLOUD 197
12.2.1.1 Need to reduce dependency on expensive on-premises infrastructure to boost demand 197
12.2.2 PRIVATE CLOUD 198
12.2.2.1 Need for enhanced security and data protection to propel market growth 198
12.2.3 MULTI-CLOUD 199
12.2.3.1 Enhanced flexibility and cost optimization to support market growth 199
12.2.4 HYBRID CLOUD 201
12.2.4.1 Cost efficiency and flexibility of hybrid cloud models to fuel market growth 201
12.3 ON-PREMISES SOLUTIONS 202
12.3.1 BETTER DATA SECURITY, PRIVACY, AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH 202
?
13 AI IN BIOTECHNOLOGY MARKET, BY END USER 204
13.1 INTRODUCTION 205
13.2 PHARMACEUTICAL COMPANIES 206
13.2.1 INNOVATION AND EFFICIENCY WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION 206
13.3 BIOTECHNOLOGY COMPANIES 207
13.3.1 ABILITY OF AI-DRIVEN INNOVATIONS FOR BETTER PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT MARKET GROWTH 207
13.4 RESEARCH INSTITUTES & LABS 208
13.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS 208
13.5 HEALTHCARE PROVIDERS 210
13.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION 210
13.6 CONTRACT RESEARCH ORGANIZATIONS 211
13.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH 211
14 AI IN BIOTECHNOLOGY MARKET, BY REGION 213
14.1 INTRODUCTION 214
14.2 NORTH AMERICA 215
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 227
14.2.2 US 227
14.2.2.1 US to dominate North American AI in biotechnology market during study period 227
14.2.3 CANADA 238
14.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market 238
14.3 EUROPE 249
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 261
14.3.2 GERMANY 261
14.3.2.1 Increased funding in startups to drive uptake of AI in biotechnology 261
14.3.3 UK 272
14.3.3.1 Increasing investments and government fund allocations to drive market 272
14.3.4 FRANCE 283
14.3.4.1 Government initiatives in France to support market growth 283
14.3.5 ITALY 294
14.3.5.1 Growing investments to create opportunities for market growth 294
14.3.6 SPAIN 305
14.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market 305
14.3.7 REST OF EUROPE 316
?
14.4 ASIA PACIFIC 327
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 340
14.4.2 JAPAN 340
14.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive Japanese market 340
14.4.3 CHINA 351
14.4.3.1 Rising foreign investments in biotechnology and biopharmaceuticals to propel market growth 351
14.4.4 INDIA 362
14.4.4.1 Increasing number of startups and growing support from government to propel market growth 362
14.4.5 SOUTH KOREA 373
14.4.5.1 Significant advances in AI integration for R&D to fuel growth 373
14.4.6 AUSTRALIA 384
14.4.6.1 Accelerating AI adoption in Australia’s biotech sector to augment market growth 384
14.4.7 REST OF ASIA PACIFIC 395
14.5 LATIN AMERICA 406
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 418
14.5.2 BRAZIL 418
14.5.2.1 Funding of biotech companies to drive Brazilian market growth 418
14.5.3 MEXICO 429
14.5.3.1 Investment inflows and strengthening AI-related education to spur market growth 429
14.5.4 REST OF LATIN AMERICA 440
14.6 MIDDLE EAST & AFRICA 451
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 463
14.6.2 GCC COUNTRIES 463
14.6.2.1 Increase in healthcare investments to support market growth 463
14.6.3 REST OF MIDDLE EAST & AFRICA 475
15 COMPETITIVE LANDSCAPE 487
15.1 INTRODUCTION 487
15.2 KEY PLAYER STRATEGY/RIGHT TO WIN 487
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET 487
15.3 REVENUE ANALYSIS, 2020?2024 490
15.4 MARKET SHARE ANALYSIS, 2024 490
15.4.1 RANKING OF KEY MARKET PLAYERS 493
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 493
15.5.1 STARS 493
15.5.2 EMERGING LEADERS 493
15.5.3 PERVASIVE PLAYERS 494
15.5.4 PARTICIPANTS 494
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 495
15.5.5.1 Company footprint 495
15.5.5.2 Region footprint 496
15.5.5.3 Component footprint 497
15.5.5.4 Function footprint 498
15.5.5.5 End-user footprint 499
15.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 500
15.6.1 PROGRESSIVE COMPANIES 500
15.6.2 RESPONSIVE COMPANIES 500
15.6.3 DYNAMIC COMPANIES 500
15.6.4 STARTING BLOCKS 500
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 502
15.6.5.1 Detailed list of key startups/SMEs 502
15.6.5.2 Competitive benchmarking of key startups/SME players 503
15.7 COMPANY VALUATION & FINANCIAL METRICS 504
15.7.1 FINANCIAL METRICS 504
15.7.2 COMPANY VALUATION 504
15.8 BRAND/PRODUCT COMPARISON 505
15.9 COMPETITIVE SCENARIO 506
15.9.1 PRODUCT LAUNCHES & UPGRADES 506
15.9.2 DEALS 507
15.9.3 EXPANSIONS 509
16 COMPANY PROFILES 510
16.1 KEY PLAYERS 510
16.1.1 NVIDIA CORPORATION 510
16.1.1.1 Business overview 510
16.1.1.2 Products offered 511
16.1.1.3 Recent developments 512
16.1.1.3.1 Product launches 512
16.1.1.3.2 Deals 512
16.1.1.4 MnM view 515
16.1.1.4.1 Right to win 515
16.1.1.4.2 Strategic choices 515
16.1.1.4.3 Weaknesses & competitive threats 515
16.1.2 ILLUMINA, INC. 516
16.1.2.1 Business overview 516
16.1.2.2 Products offered 517
16.1.2.3 Recent developments 518
16.1.2.3.1 Product launches 518
16.1.2.3.2 Deals 519
?
16.1.2.4 MnM view 521
16.1.2.4.1 Right to win 521
16.1.2.4.2 Strategic choices 521
16.1.2.4.3 Weaknesses & competitive threats 521
16.1.3 RECURSION 522
16.1.3.1 Business overview 522
16.1.3.2 Products offered 523
16.1.3.3 Recent developments 523
16.1.3.3.1 Product launches 523
16.1.3.3.2 Deals 523
16.1.3.3.3 Expansions 525
16.1.3.3.4 Other developments 526
16.1.3.4 MnM view 526
16.1.3.4.1 Right to win 526
16.1.3.4.2 Strategic choices 526
16.1.3.4.3 Weaknesses & competitive threats 526
16.1.4 SCHR?DINGER, INC. 527
16.1.4.1 Business overview 527
16.1.4.2 Products offered 528
16.1.4.3 Recent developments 529
16.1.4.3.1 Product upgrades 529
16.1.4.3.2 Deals 529
16.1.4.3.3 Other developments 531
16.1.4.4 MnM view 531
16.1.4.4.1 Right to win 531
16.1.4.4.2 Strategic choices 532
16.1.4.4.3 Weaknesses & competitive threats 532
16.1.5 BENEVOLENTAI 533
16.1.5.1 Business overview 533
16.1.5.2 Products offered 534
16.1.5.3 Recent developments 534
16.1.5.3.1 Deals 534
16.1.5.3.2 Other developments 535
16.1.5.4 MnM view 536
16.1.5.4.1 Right to win 536
16.1.5.4.2 Strategic choices 536
16.1.5.4.3 Weaknesses & competitive threats 536
16.1.6 DATA4CURE, INC. 537
16.1.6.1 Business overview 537
16.1.6.2 Products offered 537
16.1.6.3 Recent developments 538
16.1.6.3.1 Deals 538
16.1.7 QIAGEN 539
16.1.7.1 Business overview 539
16.1.7.2 Products offered 540
16.1.7.3 Recent developments 541
16.1.7.3.1 Product launches and enhancements 541
16.1.7.3.2 Deals 541
16.1.8 INSILICO MEDICINE 543
16.1.8.1 Business overview 543
16.1.8.2 Products offered 543
16.1.8.3 Recent developments 544
16.1.8.3.1 Product launches, approvals, and enhancements 544
16.1.8.3.2 Deals 545
16.1.8.3.3 Other developments 546
16.1.9 DNANEXUS, INC. 547
16.1.9.1 Business overview 547
16.1.9.2 Products offered 547
16.1.9.3 Recent developments 548
16.1.9.3.1 Deals 548
16.1.9.3.2 Other developments 550
16.1.10 TEMPUS 551
16.1.10.1 Business overview 551
16.1.10.2 Products offered 551
16.1.10.3 Recent developments 552
16.1.10.3.1 Product approvals 552
16.1.10.3.2 Deals 552
16.1.10.3.3 Other developments 554
16.1.11 SOPHIA GENETICS 555
16.1.11.1 Business overview 555
16.1.11.2 Products offered 556
16.1.11.3 Recent developments 557
16.1.11.3.1 Product launches 557
16.1.11.3.2 Deals 557
16.1.11.3.3 Other developments 559
16.1.12 PREDICTIVE ONCOLOGY 560
16.1.12.1 Business overview 560
16.1.12.2 Products offered 561
16.1.12.3 Recent developments 561
16.1.12.3.1 Product launches 561
16.1.12.3.2 Deals 561
16.1.12.3.3 Expansions 562
?
16.1.13 DEEP GENOMICS 563
16.1.13.1 Business overview 563
16.1.13.2 Products offered 563
16.1.13.3 Recent developments 564
16.1.13.3.1 Product launches 564
16.1.14 NUMEDII, INC. 565
16.1.14.1 Business overview 565
16.1.14.2 Products offered 565
16.1.15 XTALPI INC. 566
16.1.15.1 Business overview 566
16.1.15.2 Products offered 567
16.1.15.3 Recent developments 568
16.1.15.3.1 Deals 568
16.1.16 IKTOS 570
16.1.16.1 Business overview 570
16.1.16.2 Products offered 570
16.1.16.3 Recent developments 571
16.1.16.3.1 Product launches 571
16.1.16.3.2 Deals 571
16.1.16.3.3 Other developments 572
16.1.17 BPGBIO, INC. 573
16.1.17.1 Business overview 573
16.1.17.2 Products offered 573
16.1.17.3 Recent developments 574
16.1.17.3.1 Product launches 574
16.1.17.3.2 Deals 574
16.1.17.3.3 Other developments 575
16.1.18 EUROFINS DISCOVERY 576
16.1.18.1 Business overview 576
16.1.18.2 Products offered 577
16.1.18.3 Recent developments 577
16.1.18.3.1 Product launches 577
16.1.18.3.2 Deals 578
16.1.18.3.3 Expansions 579
16.2 OTHER PLAYERS 580
16.2.1 VERISIM LIFE 580
16.2.2 LIFEBIT BIOTECH INC. 580
16.2.3 VALO HEALTH 581
16.2.4 VERGE GENOMICS 581
16.2.5 LOGICA 582
16.2.6 AMERICAN CHEMICAL SOCIETY 583
16.2.7 AGANITHA AI INC. 584
17 APPENDIX 585
17.1 DISCUSSION GUIDE 585
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 592
17.3 CUSTOMIZATION OPTIONS 594
17.4 RELATED REPORTS 594
17.5 AUTHOR DETAILS 595

ページTOPに戻る

List of Tables/Graphs

＜P＞TABLE 1 AI IN BIOTECHNOLOGY MARKET: INCLUSIONS & EXCLUSIONS 55
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 57
TABLE 3 AI IN BIOTECHNOLOGY MARKET: RESEARCH ASSUMPTIONS 70
TABLE 4 AI IN BIOTECHNOLOGY MARKET: RISK ASSESSMENT 71
TABLE 5 AI IN BIOTECHNOLOGY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 81
TABLE 6 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN
AI IN BIOTECHNOLOGY MARKET, 2022?2025 82
TABLE 7 TABLE AI IN BIOTECHNOLOGY MARKET: UNMET NEEDS 89
TABLE 8 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 94
TABLE 9 FIGURE 5 AI IN BIOTECHNOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 99
TABLE 10 TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY OFFERINGS,
BY KEY PLAYER, 2024 (USD) 100
TABLE 11 TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY REGION (2024) 101
TABLE 12 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025?2026 101
TABLE 13 US ADJUSTED RECIPROCAL TARIFF RATES 105
TABLE 14 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES, 2015?2025 112
TABLE 15 TABLE AI IN BIOTECHNOLOGY MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2022?2025 114
TABLE 16 REGULATORY SCENARIO OF NORTH AMERICA 124
TABLE 17 REGULATORY SCENARIO OF EUROPE 125
TABLE 18 REGULATORY SCENARIO OF ASIA PACIFIC 126
TABLE 19 REGULATORY SCENARIO OF LATIN AMERICA 127
TABLE 20 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 127
TABLE 21 TABLE NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128
TABLE 22 TABLE EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128
TABLE 23 TABLE ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 129
TABLE 24 TABLE REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 129
TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
TOP THREE END USERS (%) 132
TABLE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS 132
TABLE 27 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET 133
TABLE 28 TABLE END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET 134
TABLE 29 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023?2029 (USD MILLION) 136
TABLE 30 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030?2035 (USD MILLION) 136
TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,
2023?2029 (USD MILLION) 137
TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,
2030?2035 (USD MILLION) 138
TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,
2023?2029 (USD MILLION) 139
TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,
2030?2035 (USD MILLION) 139
TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,
2023?2029 (USD MILLION) 140
TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,
2030?2035 (USD MILLION) 140
TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,
2023?2029 (USD MILLION) 141
TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,
2030?2035 (USD MILLION) 141
TABLE 39 CONSULTING SERVICES MARKET, BY REGION, 2023?2029 (USD MILLION) 142
TABLE 40 CONSULTING SERVICES MARKET, BY REGION, 2030?2035 (USD MILLION) 142
TABLE 41 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2023?2029 (USD MILLION) 143
TABLE 42 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2030?2035 (USD MILLION) 143
TABLE 43 TRAINING AND EDUCATION SERVICES MARKET, BY REGION,
2023?2029 (USD MILLION) 144
TABLE 44 TRAINING AND EDUCATION SERVICES MARKET, BY REGION,
2030?2035 (USD MILLION) 144
TABLE 45 POST-SALES AND MAINTENANCE SERVICES MARKET, BY REGION,
2023?2029 (USD MILLION) 145
TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES AND MAINTENANCE SERVICES, BY REGION, 2030?2035 (USD MILLION) 146
TABLE 47 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023?2029 (USD MILLION) 148
TABLE 48 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030?2035 (USD MILLION) 148
TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023?2029 (USD MILLION) 149
TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030?2035 (USD MILLION) 150
TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2023?2029 (USD MILLION) 150
TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2030?2035 (USD MILLION) 150
TABLE 53 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY 151
TABLE 54 DRUG DISCOVERY MARKET, BY TYPE, 2023?2029 (USD MILLION) 151
TABLE 55 DRUG DISCOVERY MARKET, BY TYPE, 2030?2035 (USD MILLION) 152
TABLE 56 DRUG DISCOVERY MARKET, BY REGION, 2023?2029 (USD MILLION) 152
TABLE 57 DRUG DISCOVERY MARKET, BY REGION, 2030?2035 (USD MILLION) 152
TABLE 58 MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION,
2023?2029 (USD MILLION) 153
TABLE 59 MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION,
2030?2035 (USD MILLION) 153
TABLE 60 BIOMARKER DISCOVERY MARKET, BY REGION, 2023?2029 (USD MILLION) 154
TABLE 61 BIOMARKER DISCOVERY MARKET, BY REGION, 2030?2035 (USD MILLION) 154
TABLE 62 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2023?2029 (USD MILLION) 155
TABLE 63 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2030?2035 (USD MILLION) 155
TABLE 64 CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023?2029 (USD MILLION) 156
TABLE 65 CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030?2035 (USD MILLION) 157
TABLE 66 CLINICAL DEVELOPMENT MARKET, BY REGION, 2023?2029 (USD MILLION) 157
TABLE 67 CLINICAL DEVELOPMENT MARKET, BY REGION, 2030?2035 (USD MILLION) 158
TABLE 68 TRIAL DESIGN MARKET, BY REGION, 2023?2029 (USD MILLION) 158
TABLE 69 TRIAL DESIGN MARKET, BY REGION, 2030?2035 (USD MILLION) 159
TABLE 70 SITE SELECTION MARKET, BY REGION, 2023?2029 (USD MILLION) 159
TABLE 71 SITE SELECTION MARKET, BY REGION, 2030?2035 (USD MILLION) 160
TABLE 72 RECRUITMENT MARKET, BY REGION, 2023?2029 (USD MILLION) 160
TABLE 73 RECRUITMENT MARKET, BY REGION, 2030?2035 (USD MILLION) 161
TABLE 74 CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2023?2029 (USD MILLION) 161
TABLE 75 CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2030?2035 (USD MILLION) 162
TABLE 76 PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION,
2023?2029 (USD MILLION) 162
TABLE 77 PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION,
2030?2035 (USD MILLION) 163
TABLE 78 MONITORING & DRUG ADHERENCE MARKET, BY REGION,
2023?2029 (USD MILLION) 163
TABLE 79 MONITORING & DRUG ADHERENCE MARKET, BY REGION,
2030?2035 (USD MILLION) 164
TABLE 80 REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION,
2023?2029 (USD MILLION) 164
TABLE 81 REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION,
2030?2035 (USD MILLION) 165
TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2023?2029 (USD MILLION) 166
TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2030?2035 (USD MILLION) 166
TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023?2029 (USD MILLION) 167
TABLE 85 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030?2035 (USD MILLION) 167
TABLE 86 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,
BY REGION, 2023?2029 (USD MILLION) 168
TABLE 87 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,
BY REGION, 2030?2035 (USD MILLION) 168
TABLE 88 SUPPLY CHAIN PLANNING MARKET, BY REGION, 2023?2029 (USD MILLION) 169
TABLE 89 SUPPLY CHAIN PLANNING MARKET, BY REGION, 2030?2035 (USD MILLION) 169
TABLE 90 INVENTORY MANAGEMENT MARKET, BY REGION, 2023?2029 (USD MILLION) 170
TABLE 91 INVENTORY MANAGEMENT MARKET, BY REGION, 2030?2035 (USD MILLION) 170
TABLE 92 LOGISTICS OPTIMIZATION MARKET, BY REGION, 2023?2029 (USD MILLION) 171
TABLE 93 LOGISTICS OPTIMIZATION MARKET, BY REGION, 2030?2035 (USD MILLION) 171
TABLE 94 DEMAND FORECASTING MARKET, BY REGION, 2023?2029 (USD MILLION) 172
TABLE 95 DEMAND FORECASTING MARKET, BY REGION, 2030?2035 (USD MILLION) 172
TABLE 96 PREDICTIVE MAINTENANCE MARKET, BY REGION, 2023?2029 (USD MILLION) 173
TABLE 97 PREDICTIVE MAINTENANCE MARKET, BY REGION, 2030?2035 (USD MILLION) 173
TABLE 98 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2023?2029 (USD MILLION) 174
TABLE 99 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2030?2035 (USD MILLION) 174
TABLE 100 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE,
2023?2029 (USD MILLION) 175
TABLE 101 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE,
2030?2035 (USD MILLION) 175
TABLE 102 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION,
2023?2029 (USD MILLION) 176
TABLE 103 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION,
2030?2035 (USD MILLION) 176
TABLE 104 LAUNCH COORDINATION MARKET, BY REGION, 2023?2029 (USD MILLION) 177
TABLE 105 LAUNCH COORDINATION MARKET, BY REGION, 2030?2035 (USD MILLION) 177
TABLE 106 PATIENT ENGAGEMENT MARKET, BY REGION, 2023?2029 (USD MILLION) 178
TABLE 107 PATIENT ENGAGEMENT MARKET, BY REGION, 2030?2035 (USD MILLION) 178
TABLE 108 MARKETING OPERATIONS MARKET, BY REGION, 2023?2029 (USD MILLION) 179
TABLE 109 MARKETING OPERATIONS MARKET, BY REGION, 2030?2035 (USD MILLION) 179
TABLE 110 PREDICTIVE PRICING MARKET, BY REGION, 2023?2029 (USD MILLION) 180
TABLE 111 PREDICTIVE PRICING MARKET, BY REGION, 2030?2035 (USD MILLION) 180
TABLE 112 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023?2029 (USD MILLION) 181
TABLE 113 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030?2035 (USD MILLION) 181
TABLE 114 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2023?2029 (USD MILLION) 182
TABLE 115 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2030?2035 (USD MILLION) 182
TABLE 116 MEDICATION ADHERENCE MARKET, BY REGION, 2023?2029 (USD MILLION) 183
TABLE 117 MEDICATION ADHERENCE MARKET, BY REGION, 2030?2035 (USD MILLION) 183
TABLE 118 ADVERSE EVENT REPORTING MARKET, BY REGION, 2023?2029 (USD MILLION) 184
TABLE 119 ADVERSE EVENT REPORTING MARKET, BY REGION, 2030?2035 (USD MILLION) 184
TABLE 120 PATIENT MONITORING MARKET, BY REGION, 2023?2029 (USD MILLION) 185
TABLE 121 PATIENT MONITORING MARKET, BY REGION, 2030?2035 (USD MILLION) 185
TABLE 122 COMPLIANCE MONITORING MARKET, BY REGION, 2023?2029 (USD MILLION) 186
TABLE 123 COMPLIANCE MONITORING MARKET, BY REGION, 2030?2035 (USD MILLION) 186
TABLE 124 PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2023?2029 (USD MILLION) 187
TABLE 125 PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2030?2035 (USD MILLION) 187
TABLE 126 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2023?2029 (USD MILLION) 188
TABLE 127 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2030?2035 (USD MILLION) 188
TABLE 128 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION,
2023?2029 (USD MILLION) 189
TABLE 129 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION,
2030?2035 (USD MILLION) 189
TABLE 130 RISK MANAGEMENT MARKET, BY REGION, 2023?2029 (USD MILLION) 190
TABLE 131 RISK MANAGEMENT MARKET, BY REGION, 2030?2035 (USD MILLION) 190
TABLE 132 COMPLIANCE MONITORING MARKET, BY REGION, 2023?2029 (USD MILLION) 191
TABLE 133 COMPLIANCE MONITORING MARKET, BY REGION, 2030?2035 (USD MILLION) 191
TABLE 134 SALES FORCE OPTIMIZATION MARKET, BY REGION, 2023?2029 (USD MILLION) 192
TABLE 135 SALES FORCE OPTIMIZATION MARKET, BY REGION, 2030?2035 (USD MILLION) 192
TABLE 136 OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2023?2029 (USD MILLION) 193
TABLE 137 OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2030?2035 (USD MILLION) 193
TABLE 138 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2023?2029 (USD MILLION) 195
TABLE 139 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2030?2035 (USD MILLION) 195
TABLE 140 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,
2023?2029 (USD MILLION) 196
TABLE 141 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,
2030?2035 (USD MILLION) 196
TABLE 142 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2023?2029 (USD MILLION) 196
TABLE 143 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2030?2035 (USD MILLION) 197
TABLE 144 PUBLIC CLOUD MARKET, BY REGION, 2023?2029 (USD MILLION) 198
TABLE 145 PUBLIC CLOUD MARKET, BY REGION, 2030?2035 (USD MILLION) 198
TABLE 146 PRIVATE CLOUD MARKET, BY REGION, 2023?2029 (USD MILLION) 199
TABLE 147 PRIVATE CLOUD MARKET, BY REGION, 2030?2035 (USD MILLION) 199
TABLE 148 MULTI CLOUD MARKET, BY REGION, 2023?2029 (USD MILLION) 200
TABLE 149 MULTI CLOUD MARKET, BY REGION, 2030?2035 (USD MILLION) 200
TABLE 150 HYBRID CLOUD MARKET, BY REGION, 2023?2029 (USD MILLION) 201
TABLE 151 HYBRID CLOUD MARKET, BY REGION, 2030?2035 (USD MILLION) 201
TABLE 152 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2023?2029 (USD MILLION) 202
TABLE 153 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2030?2035 (USD MILLION) 203
TABLE 154 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023?2029 (USD MILLION) 205
TABLE 155 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030?2035 (USD MILLION) 205
TABLE 156 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023?2029 (USD MILLION) 206
TABLE 157 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2030?2035 (USD MILLION) 207
TABLE 158 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2023?2029 (USD MILLION) 208
TABLE 159 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2030?2035 (USD MILLION) 208
TABLE 160 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2023?2029 (USD MILLION) 209
TABLE 161 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2030?2035 (USD MILLION) 209
TABLE 162 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023?2029 (USD MILLION) 210
TABLE 163 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2030?2035 (USD MILLION) 211
TABLE 164 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2023?2029 (USD MILLION) 212
TABLE 165 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2030?2035 (USD MILLION) 212
TABLE 166 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2023?2029 (USD MILLION) 214
TABLE 167 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2030?2035 (USD MILLION) 214
TABLE 168 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2023?2029 (USD MILLION) 216
TABLE 169 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2030?2035 (USD MILLION) 216
TABLE 170 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2023?2029 (USD MILLION) 216
TABLE 171 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2030?2035 (USD MILLION) 217
TABLE 172 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2023?2029 (USD MILLION) 217
TABLE 173 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2030?2035 (USD MILLION) 218
TABLE 174 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2023?2029 (USD MILLION) 218
TABLE 175 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2030?2035 (USD MILLION) 219
TABLE 176 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023?2029 (USD MILLION) 219
TABLE 177 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030?2035 (USD MILLION) 219
TABLE 178 NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE,
2023?2029 (USD MILLION) 220
TABLE 179 NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE,
2030?2035 (USD MILLION) 220
TABLE 180 NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,
2023?2029 (USD MILLION) 221
TABLE 181 NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,
2030?2035 (USD MILLION) 221
TABLE 182 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023?2029 (USD MILLION) 222
TABLE 183 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030?2035 (USD MILLION) 222
TABLE 184 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023?2029 (USD MILLION) 223
TABLE 185 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030?2035 (USD MILLION) 223
TABLE 186 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023?2029 (USD MILLION) 223
TABLE 187 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030?2035 (USD MILLION) 224
TABLE 188 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023?2029 (USD MILLION) 224
TABLE 189 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030?2035 (USD MILLION) 225
TABLE 190 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023?2029 (USD MILLION) 225
TABLE 191 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030?2035 (USD MILLION) 225
TABLE 192 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023?2029 (USD MILLION) 226
TABLE 193 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030?2035 (USD MILLION) 226
TABLE 194 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2023?2029 (USD MILLION) 226
TABLE 195 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2030?2035 (USD MILLION) 227
TABLE 196 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023?2029 (USD MILLION) 228
TABLE 197 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030?2035 (USD MILLION) 228
TABLE 198 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2023?2029 (USD MILLION) 228
TABLE 199 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2030?2035 (USD MILLION) 229
TABLE 200 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023?2029 (USD MILLION) 229
TABLE 201 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030?2035 (USD MILLION) 230
TABLE 202 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023?2029 (USD MILLION) 230
TABLE 203 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030?2035 (USD MILLION) 230
TABLE 204 US: DRUG DISCOVERY MARKET, BY TYPE, 2023?2029 (USD MILLION) 231
TABLE 205 US: DRUG DISCOVERY MARKET, BY TYPE, 2030?2035 (USD MILLION) 231
TABLE 206 US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023?2029 (USD MILLION) 231
TABLE 207 US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030?2035 (USD MILLION) 232
TABLE 208 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,
BY TYPE, 2023?2029 (USD MILLION) 232
TABLE 209 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,
BY TYPE, 2030?2035 (USD MILLION) 233
TABLE 210 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023?2029 (USD MILLION) 233
TABLE 211 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030?2035 (USD MILLION) 234
TABLE 212 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023?2029 (USD MILLION) 234
TABLE 213 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030?2035 (USD MILLION) 235
TABLE 214 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2023?2029 (USD MILLION) 235
TABLE 215 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2030?2035 (USD MILLION) 236
TABLE 216 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2023?2029 (USD MILLION) 236
TABLE 217 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2030?2035 (USD MILLION) 236
TABLE 218 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023?2029 (USD MILLION) 237
TABLE 219 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030?2035 (USD MILLION) 237
TABLE 220 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023?2029 (USD MILLION) 237
TABLE 221 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030?2035 (USD MILLION) 238
TABLE 222 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2023?2029 (USD MILLION) 238
TABLE 223 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2030?2035 (USD MILLION) 239
TABLE 224 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2023?2029 (USD MILLION) 239
TABLE 225 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2030?2035 (USD MILLION) 239
TABLE 226 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2023?2029 (USD MILLION) 240
TABLE 227 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2030?2035 (USD MILLION) 240
TABLE 228 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,
BY TYPE, 2023?2029 (USD MILLION) 241
TABLE 229 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,
BY TYPE, 2030?2035 (USD MILLION) 241
TABLE 230 CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2023?2029 (USD MILLION) 241
TABLE 231 CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2030?2035 (USD MILLION) 242
TABLE 232 CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023?2029 (USD MILLION) 242
TABLE 233 CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030?2035 (USD MILLION) 243
TABLE 234 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023?2029 (USD MILLION) 243
TABLE 235 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030?2035 (USD MILLION) 244
TABLE 236 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023?2029 (USD MILLION) 244
TABLE 237 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030?2035 (USD MILLION) 245
TABLE 238 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023?2029 (USD MILLION) 245
TABLE 239 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030?2035 (USD MILLION) 246
TABLE 240 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2023?2029 (USD MILLION) 246
TABLE 241 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2030?2035 (USD MILLION) 247
TABLE 242 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2023?2029 (USD MILLION) 247
TABLE 243 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2030?2035 (USD MILLION) 247
TABLE 244 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2023?2029 (USD MILLION) 248
TABLE 245 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2030?2035 (USD MILLION) 248
TABLE 246 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2023?2029 (USD MILLION) 248
TABLE 247 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2030?2035 (USD MILLION) 249
TABLE 248 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2023?2029 (USD MILLION) 250
TABLE 249 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2030?2035 (USD MILLION) 250
TABLE 250 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2023?2029 (USD MILLION) 251
TABLE 251 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2030?2035 (USD MILLION) 251
TABLE 252 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2023?2029 (USD MILLION) 251
TABLE 253 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2030?2035 (USD MILLION) 252
TABLE 254 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2023?2029 (USD MILLION) 252
TABLE 255 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2030?2035 (USD MILLION) 253
TABLE 256 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,
BY TYPE, 2023?2029 (USD MILLION) 253
TABLE 257 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,
BY TYPE, 2030?2035 (USD MILLION) 253
TABLE 258 EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2023?2029 (USD MILLION) 254
TABLE 259 EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2030?2035 (USD MILLION) 254
TABLE 260 EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023?2029 (USD MILLION) 254
TABLE 261 EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030?2035 (USD MILLION) 255
TABLE 262 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023?2029 (USD MILLION) 255
TABLE 263 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030?2035 (USD MILLION) 256
TABLE 264 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023?2029 (USD MILLION) 256
TABLE 265 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030?2035 (USD MILLION) 257
TABLE 266 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023?2029 (USD MILLION) 257
TABLE 267 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030?2035 (USD MILLION) 258
TABLE 268 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2023?2029 (USD MILLION) 258
TABLE 269 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2030?2035 (USD MILLION) 259
TABLE 270 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2023?2029 (USD MILLION) 259
TABLE 271 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2030?2035 (USD MILLION) 259
TABLE 272 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2023?2029 (USD MILLION) 260
TABLE 273 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2030?2035 (USD MILLION) 260
TABLE 274 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2023?2029 (USD MILLION) 260
TABLE 275 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2030?2035 (USD MILLION) 261
TABLE 276 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2023?2029 (USD MILLION) 262
TABLE 277 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2030?2035 (USD MILLION) 262
TABLE 278 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2023?2029 (USD MILLION) 262
TABLE 279 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2030?2035 (USD MILLION) 263
TABLE 280 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2023?2029 (USD MILLION) 263
TABLE 281 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2030?2035 (USD MILLION) 264
TABLE 282 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,
BY TYPE, 2023?2029 (USD MILLION) 264
TABLE 283 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,
BY TYPE, 2030?2035 (USD MILLION) 264
TABLE 284 GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2023?2029 (USD MILLION) 265
TABLE 285 GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2030?2035 (USD MILLION) 265
TABLE 286 GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE,
2023?2029 (USD MILLION) 265
TABLE 287 GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE,
2030?2035 (USD MILLION) 266
TABLE 288 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023?2029 (USD MILLION) 266
TABLE 289 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030?2035 (USD MILLION) 267
TABLE 290 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,
BY TYPE, 2023?2029 (USD MILLION) 267
TABLE 291 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,
BY TYPE, 2030?2035 (USD MILLION) 268
TABLE 292 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023?2029 (USD MILLION) 268
TABLE 293 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030?2035 (USD MILLION) 269
TABLE 294 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2023?2029 (USD MILLION) 269
TABLE 295 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2030?2035 (USD MILLION) 270
TABLE 296 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2023?2029 (USD MILLION) 270
TABLE 297 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2030?2035 (USD MILLION) 270
TABLE 298 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2023?2029 (USD MILLION) 271
TABLE 299 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2030?2035 (USD MILLION) 271
TABLE 300 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2023?2029 (USD MILLION) 271
TABLE 301 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2030?2035 (USD MILLION) 272TABLE 302 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023?2029 (USD MILLION) 272
TABLE 303 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030?2035 (USD MILLION) 273
TABLE 304 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2023?2029 (USD MILLION) 273
TABLE 305 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2030?2035 (USD MILLION) 273
TABLE 306 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023?2029 (USD MILLION) 274
TABLE 307 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030?2035 (USD MILLION) 274
TABLE 308 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023?2029 (USD MILLION) 275
TABLE 309 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030?2035 (USD MILLION) 275
TABLE 310 UK: DRUG DISCOVERY MARKET, BY TYPE, 2023?2029 (USD MILLION) 275
TABLE 311 UK: DRUG DISCOVERY MARKET, BY TYPE, 2030?2035 (USD MILLION) 276
TABLE 312 UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023?2029 (USD MILLION) 276
TABLE 313 UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030?2035 (USD MILLION) 277
TABLE 314 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,
BY TYPE, 2023?2029 (USD MILLION) 277
TABLE 315 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,
BY TYPE, 2030?2035 (USD MILLION) 278
TABLE 316 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023?2029 (USD MILLION) 278
TABLE 317 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030?2035 (USD MILLION) 279
TABLE 318 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023?2029 (USD MILLION) 279
TABLE 319 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030?2035 (USD MILLION) 280
TABLE 320 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2023?2029 (USD MILLION) 280
TABLE 321 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2030?2035 (USD MILLION) 281
TABLE 322 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2023?2029 (USD MILLION) 281
TABLE 323 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2030?2035 (USD MILLION) 281
TABLE 324 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023?2029 (USD MILLION) 282
TABLE 325 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030?2035 (USD MILLION) 282
TABLE 326 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023?2029 (USD MILLION) 282
TABLE 327 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030?2035 (USD MILLION) 283
TABLE 328 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2023?2029 (USD MILLION) 284
TABLE 329 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2030?2035 (USD MILLION) 284
TABLE 330 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2023?2029 (USD MILLION) 284
TABLE 331 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2030?2035 (USD MILLION) 285
TABLE 332 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2023?2029 (USD MILLION) 285
TABLE 333 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2030?2035 (USD MILLION) 286
TABLE 334 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,
BY TYPE, 2023?2029 (USD MILLION) 286
TABLE 335 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,
BY TYPE, 2030?2035 (USD MILLION) 286
TABLE 336 FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2023?2029 (USD MILLION) 287
TABLE 337 FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2030?2035 (USD MILLION) 287
TABLE 338 FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023?2029 (USD MILLION) 287
TABLE 339 FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030?2035 (USD MILLION) 288
TABLE 340 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023?2029 (USD MILLION) 288
TABLE 341 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030?2035 (USD MILLION) 289
TABLE 342 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023?2029 (USD MILLION) 289
TABLE 343 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030?2035 (USD MILLION) 290
TABLE 344 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023?2029 (USD MILLION) 290
TABLE 345 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030?2035 (USD MILLION) 291
TABLE 346 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2023?2029 (USD MILLION) 291
TABLE 347 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,
2030?2035 (USD MILLION) 292
TABLE 348 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2023?2029 (USD MILLION) 292
TABLE 349 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2030?2035 (USD MILLION) 292
TABLE 350 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023?2029 (USD MILLION) 293
TABLE 351 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030?2035 (USD MILLION) 293
TABLE 352 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2023?2029 (USD MILLION) 293
TABLE 353 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2030?2035 (USD MILLION) 294
TABLE 354 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023?2029 (USD MILLION) 295
TABLE 355 ITALY: AI IN BIOTECHN